Citius Pharmaceuticals to Participate in September 2026 Investor Conferences
Citius Pharmaceuticals (CTXR) announced that Chairman and CEO Leonard Mazur will present and host one-on-one investor meetings at two New York City investor conferences in September 2026.
Rhea-AI Summary
Citius Pharmaceuticals (CTXR) announced that Chairman and CEO Leonard Mazur will present and host one-on-one investor meetings at two New York City investor conferences in September 2026.
He will discuss the company’s business, recent developments, the ongoing commercialization of LYMPHIR by majority-owned subsidiary Citius Oncology (CTOR), and the progress of its late-stage pipeline. Mazur is scheduled to speak at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference on September 9, 2026, from 3:15 pm to 4:00 pm ET at The Westin New York Grand Central, and at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, from 2:00 pm to 2:30 pm ET at the Lotte New York Palace Hotel. Both appearances are expected to have webcast access via conference-provided links, and presentation times are subject to change based on the final agendas.
Positive
- None.
Negative
- None.
News Market Reaction – CTXR
In the Sep 3 session, CTXR gained 3.88%, reflecting a moderate positive market reaction. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 14 | Citius Oncology earnings | Neutral | -24.9% | Commercial revenue and adoption growth were offset by losses and financing-related liquidity concerns. |
| Aug 14 | Citius Pharma earnings | Neutral | -24.9% | LYMPHIR traction accompanied quarterly losses and ongoing capital requirements. |
| Aug 12 | Board appointment | Positive | +7.5% | An independent director appointment expanded Citius Oncology's board to nine members. |
| Aug 05 | Commercial momentum update | Positive | +25.4% | LYMPHIR availability and institutional ordering activity expanded during the commercial rollout. |
| Jul 21 | Commercial organization update | Positive | +13.5% | Citius Oncology reported nationwide field-force deployment and expanding LYMPHIR adoption. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Operational and governance updates aligned with gains, while the mixed August 14 earnings update diverged as shares declined 24.95%.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Chairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference and Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
During his presentations and investor meetings, Mr. Mazur will provide an overview of the Company's business and recent developments, including the ongoing commercialization of LYMPHIR® (denileukin diftitox-cxdl) by the Company's majority-owned subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR), and the continued advancement of the Company's late-stage pipeline.
Moody Capital Solutions Conference:
- Conference: Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
- Dates: September 9–10, 2026
- Location: The Westin New York Grand Central,
New York, NY - Presentation Date & Time: Wednesday, September 9, 2026, 3:15 pm – 4:00 pm ET
- Webcast: webcast link
H.C. Wainwright Conference:
- Conference: H.C. Wainwright 28th Annual Global Investment Conference
- Dates: September 14–16, 2026
- Location: Lotte New York Palace Hotel,
New York, NY - Presentation Date & Time: Tuesday, September 15, 2026, 2:00 pm – 2:30 pm ET
- Webcast: webcast link
Please note that the presentation dates and times are subject to change. Participants should refer to the final program agenda for up-to-date information.
Investors interested in scheduling a one-on-one meeting with management should contact their conference representative or the Company's investor relations team.
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. Citius Pharma owns approximately
About Citius Oncology, Inc.
Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds
Investor Contact:
Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113
Media Contact:
STiR-communications
Greg Salsburg
Greg@STiR-communications.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-participate-in-september-2026-investor-conferences-302868503.html
SOURCE Citius Pharmaceuticals, Inc.
FAQ
What investor conferences will Citius Pharmaceuticals (CTXR) participate in during September 2026?
Citius Pharmaceuticals will participate in two New York City investor events in September 2026: the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference and the H.C. Wainwright 28th Annual Global Investment Conference. Chairman and CEO Leonard Mazur will present at both.
When is Citius Pharmaceuticals’ presentation at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference?
Citius Pharmaceuticals is scheduled to present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference on Wednesday, September 9, 2026, from 3:15 pm to 4:00 pm ET at The Westin New York Grand Central in New York, NY.
When will Citius Pharmaceuticals (CTXR) present at the H.C. Wainwright 28th Annual Global Investment Conference?
At the H.C. Wainwright 28th Annual Global Investment Conference, Citius Pharmaceuticals is scheduled to present on Tuesday, September 15, 2026, from 2:00 pm to 2:30 pm ET at the Lotte New York Palace Hotel in New York, NY.
What topics will Citius Pharmaceuticals’ CEO cover at the September 2026 investor conferences?
Leonard Mazur plans to provide an overview of Citius Pharmaceuticals’ business and recent developments, including the ongoing commercialization of LYMPHIR (denileukin diftitox-cxdl) by majority-owned subsidiary Citius Oncology (CTOR) and the continued advancement of the company’s late-stage pipeline.
Will Citius Pharmaceuticals’ September 2026 conference presentations be available via webcast?
Both the Moody Capital Solutions and H.C. Wainwright presentations are expected to have webcast access through their respective webcast links. The company advises participants to check the final conference program agenda for the latest webcast details and any schedule changes.
How can investors schedule one-on-one meetings with Citius Pharmaceuticals’ management at the September 2026 conferences?
Investors interested in one-on-one meetings with Citius Pharmaceuticals’ management are advised to contact either their conference representative or the company’s investor relations team to arrange a meeting during the conferences.
Are the Citius Pharmaceuticals (CTXR) conference presentation times in September 2026 final?
The company notes that presentation dates and times are subject to change. Participants should refer to the conferences’ final program agendas for the most up-to-date scheduling information before attending or joining the webcasts.